EUVIMEDEUVIMED entdecken
Crossref

FDA Grants Breakthrough Device Designation to AutoGenomics’ INFINITI® Neural Response Panel for the Identification of the Risk of Opioid Dependency

Journal of Anesthesia & Pain Medicine · 2018

DOI: 10.33140/japm.03.03.05 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Anesthesia & Pain Medicine, 2018.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

June 04, 2018 AutoGenomics, Inc., based in Carlsbad, CA, announced that its INFINITI® Neural Response Panel has been granted designation as a Breakthrough Device by the US Food and Drug Administration (FDA). The INFINITI® Neural Response Panel is a qualitative in vitro diagnostic test for the identification of patients who may be at risk for opioid dependency. The Panel is designed to identify 16 genetic mutations involved in the brain reward pathways that are associated with increased risk of opioid use disorder, and is intended for use by physicians as an aid for safe and effective pain management

Zitieren

APA

(2018). FDA Grants Breakthrough Device Designation to AutoGenomics’ INFINITI® Neural Response Panel for the Identification of the Risk of Opioid Dependency. Journal of Anesthesia & Pain Medicine. https://doi.org/10.33140/japm.03.03.05

Vancouver

FDA Grants Breakthrough Device Designation to AutoGenomics’ INFINITI® Neural Response Panel for the Identification of the Risk of Opioid Dependency. Journal of Anesthesia & Pain Medicine. 2018. doi:10.33140/japm.03.03.05

BibTeX
@article{euvimed2018,
  title = {FDA Grants Breakthrough Device Designation to AutoGenomics’ INFINITI® Neural Response Panel for the Identification of the Risk of Opioid Dependency},
  journal = {Journal of Anesthesia & Pain Medicine},
  year = {2018},
  doi = {10.33140/japm.03.03.05}
}
Kostenlos starten →